<img src="https://trc.taboola.com/1321591/log/3/unip?en=page_view" width="0" height="0" style="display:none">
Fact Check Library

Fact Check with Logically.

Download the Free App Today




Paediatric Covid-19 patients will be enrolled in remdesivir clinical trial.

Paediatric patients with moderate-to-severe Covid-19 will be enrolled in a late-stage study testing the effects of remdesivir in children.

Remdesivir is an antiviral medicine that was being developed for the treatment of Ebola. Its maker, Gilead Sciences, has been working with researchers and governments and conducting clinical trials for the drug. On June 18, Gilead announced that they are ready to conduct a Phase II/III clinical trial of remdesivir to treat paediatric patients hospitalised with Covid-19. They further said that they will assess the 'safety, tolerability, pharmacokinetics and efficacy' of the drug in around 50 paediatric patients with moderate-to-severe Covid-19, including newborns and adolescents. The trial is expected to be completed by December 2020.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.

Have a question or correction?

Please tell us if you think this claim had been misjudged or requires correction by sending us evidence to support your error claim. We will revisit our evidence and verdict and do some additional research to double check if we can verify the new information

Fact Check of the Day


COVID-19 vaccines prevent infection in just 12 percent of those vaccinated.